Linvoseltamab (Lynozyfic)

This section covers linvoseltamab (brand name Lynozyfic), a targeted immunotherapy for multiple myeloma that has returned or stopped responding to prior treatments. It is a bispecific antibody—a medicine designed to connect your body's immune cells directly to myeloma cells to help destroy the cancer. Because this treatment comes ready to use without needing to be custom-made from your own cells, it is readily available when your care team decides it is time to start. Here, you will find information about what to expect during treatment, potential side effects, and how dosing schedules may adjust to once every four weeks if your cancer responds well.